Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 4.2% – Should You Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s share price was down 4.2% on Tuesday . The stock traded as low as $11.88 and last traded at $11.87. Approximately 129,341 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 1,352,046 shares. The stock had previously closed at $12.39.

Wall Street Analyst Weigh In

DYN has been the topic of a number of analyst reports. Raymond James upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Robert W. Baird started coverage on Dyne Therapeutics in a report on Friday, December 13th. They issued an “outperform” rating and a $46.00 price objective for the company. Guggenheim reiterated a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Chardan Capital restated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research report on Monday, March 17th. Finally, HC Wainwright restated a “buy” rating and set a $46.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Dyne Therapeutics has an average rating of “Moderate Buy” and an average target price of $47.46.

Dyne Therapeutics Stock Down 7.3 %

The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -3.23 and a beta of 1.11. The stock has a 50 day moving average price of $13.54 and a 200 day moving average price of $23.99.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.04. Sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Activity at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the sale, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold 6,237 shares of company stock worth $77,760 over the last three months. Company insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Several large investors have recently modified their holdings of DYN. Quantbot Technologies LP bought a new stake in Dyne Therapeutics during the third quarter valued at $34,000. Point72 DIFC Ltd bought a new stake in shares of Dyne Therapeutics during the 3rd quarter valued at about $36,000. GF Fund Management CO. LTD. acquired a new stake in Dyne Therapeutics during the fourth quarter worth approximately $50,000. KBC Group NV increased its holdings in Dyne Therapeutics by 45.3% in the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after purchasing an additional 978 shares in the last quarter. Finally, Quest Partners LLC increased its holdings in Dyne Therapeutics by 898.3% in the third quarter. Quest Partners LLC now owns 3,434 shares of the company’s stock worth $123,000 after purchasing an additional 3,090 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.